Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 16, 2024, 12:35 a.m. and Nov. 23, 2024, 12:35 a.m. from: Gastrointestinal Device Market.

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


Vitara Biomedical Raises $50 Million in Additional Financing and Names Kim Rodriguez as New Chief Executive Officer

Document Date: Nov. 19, 2024, 1 p.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity / Type: Investment / Region: United States
Investor: Target: Document Extract: Vitara Biomedical, a privately held company developing breakthrough technology intended to transform neonatal care, today announced the closing of a $ 50M funding round.
Document Source: https://www.businesswire.com/news/home/20241119736664/en/Vitara-Biomedical-Raises-50-Million-in-Additional-Financing-and-Names-Kim-Rodriguez-as-New-Chief-Executive-Officer (archive.org page / archive.org listing)


DeBogy Molecular Announces New Capital Raise to Bring Innovative Antimicrobial Technology to Market

Document Date: Nov. 19, 2024, noon / Source: Business Wire
Activity Class: CorporateFinanceActivity / Type: Investment / Region: United States
Target: Document Extract: DeBogy Molecular, Inc, a privately held biotech that specializes in antimicrobial surface modification, announced their Board of Directors has approved a new capital raise to support the Company's plans to seek FDA approval and marketing of its patented technology with their medical device industry partners.
Document Source: https://www.businesswire.com/news/home/20241119673074/en/DeBogy-Molecular-Announces-New-Capital-Raise-to-Bring-Innovative-Antimicrobial-Technology-to-Market (archive.org page / archive.org listing)


SurgiBox Announces Strategic Partnership with Accord International to Expand into Japanese Market

Document Date: Nov. 17, 2024, 11:17 p.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity / Region: Japan
Partnership: Document Extract: With regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) already secured, this partnership marks a significant step in expanding access to sterile, portable surgical environments across Japan. This collaboration will enable the distribution of SurgiField, an innovative portable and inflatable sterile environment designed for safe surgeries in a variety of settings. Through this partnership, SurgiBox and Accord International aim to meet the demand for adaptable surgical solutions among hospitals, emergency medical teams, and healthcare providers in remote and disaster-prone areas throughout Japan. Dr. Tomohisa Shoko, M.D., Ph.D., Professor and Director of Emergency and Critical Care Medicine at Tokyo Women's University Adachi Medical Center, recently tested the SurgiField system in simulated field surgeries, including use in an ambulance. He praised the technology's adaptability, noting its potential for safe surgeries outside traditional operating rooms-a first in Japan.
Document Source: https://www.globenewswire.com/news-release/2024/11/17/2982405/0/en/SurgiBox-Announces-Strategic-Partnership-with-Accord-International-to-Expand-into-Japanese-Market.html (archive.org page / archive.org listing)


Laerdal Medical announces strategic partnership with the American Hospital Association to enhance quality and safety in healthcare

Document Date: Nov. 19, 2024, 2 p.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: WAPPINGER FALLS, N.Y., Nov. 19, 2024 /PRNewswire/ - Laerdal Medical, a global leader in healthcare education, training, and therapy solutions, is excited to announce a new partnership with the American Hospital Association (AHA) . This collaboration in conjunction with the AHA's Patient Safety Initiative, will support efforts to strengthen quality and patient safety in hospitals across the United States. Laerdal Medical and the AHA share common goals to advance equitable care and health improvement for all. " All hospitals and health systems strive to deliver safe, high-quality care to every patient they serve ," said AHA Chief Physician Executive Chris DeRienzo, M.D. " We are proud of the progress hospitals have made but recognize there is always more work to be done to improve patient outcomes, advance equity of care and enrich the patient experience ."
Document Source: https://www.prnewswire.com/news-releases/laerdal-medical-announces-strategic-partnership-with-the-american-hospital-association-to-enhance-quality-and-safety-in-healthcare-302308877.html (archive.org page / archive.org listing)


Laerdal Medical announces strategic partnership with the American Hospital Association to enhance quality and safety in healthcare

Document Date: Nov. 19, 2024, 2 p.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: Laerdal Medical announces strategic partnership with the American Hospital Association to enhance quality in healthcare Post this. The partnership aligns closely with Laerdal's commitment to improving patient outcomes and complements the company's longstanding partnership with the National League for Nursing (NLN) in the professional education segment. Together with the AHA, Laerdal will bring novel solutions and evidence - based practices to hospitals, with a particular focus on innovation, including in-situ simulation programs and quality performance reviews through Laerdal's Accelerate program. Key elements of the partnership include Laerdal's participation in the prestigious American Hospital Association Quest for Quality Award review committee, where the company will contribute to the selection of award recipients. Additionally, Laerdal's Accelerate program will be integrated into site audits at finalist locations, offering hospitals a new tool to assess and improve team and quality performance.
Document Source: https://www.prnewswire.com/news-releases/laerdal-medical-announces-strategic-partnership-with-the-american-hospital-association-to-enhance-quality-and-safety-in-healthcare-302308877.html (archive.org page / archive.org listing)


Smart ring maker Oura hits a $5bn valuation after raising $75m

Document Date: Nov. 19, 2024, 12:45 p.m. / Source: Sifted
Activity Class: CorporateFinanceActivity / Type: Investment / Region: Japan
Investor: Target: Document Extract: Smart ring maker Oura has hit a $ 5.2bn valuation after raising a $ 75m Series D from US continuous glucose monitoring (CGM) giant Dexcom.
Document Source: https://sifted.eu/articles/smart-ring-maker-oura-raises-75m-news (archive.org page / archive.org listing)


Smart ring maker Oura hits a $5bn valuation after raising $75m

Document Date: Nov. 19, 2024, 12:45 p.m. / Source: Sifted
Activity Class: CorporateFinanceActivity / Type: Ipo / Region: Japan
Vendor: Document Extract: Smart ring maker Oura hits a $ 5bn valuation after raising $ 75m.
Document Source: https://sifted.eu/articles/smart-ring-maker-oura-raises-75m-news (archive.org page / archive.org listing)


Quantum-Si and Planet Innovation to Partner on Proteus™

Document Date: Nov. 20, 2024, 11 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership: Document Extract: Through this expanded partnership, Planet Innovation will support the development of Quantum-Si's Proteus instrument and serve as the contract manufacturing partner to ensure a seamless transition from development into commercialization. " We are thrilled to expand our partnership with Planet Innovation and leverage their global scale and expertise to accelerate the development and commercialization of Proteus ," said Jeff Hawkins, President and CEO of Quantum-Si. " We believe that partnering with Planet Innovation will allow us to deliver this novel instrument to the market on a timeline of under two years ." " Planet Innovation is proud to support Quantum-Si in developing their new proteomics platform. We have a large, established team with a proven track record in developing world-first life science platforms that are disruptive, compliant and commercialized in record time.
Document Source: https://www.businesswire.com/news/home/20241120378566/en/Quantum-Si-and-Planet-Innovation-to-Partner-on-Proteus%25E2%2584%25A2 (archive.org page / archive.org listing)


Quantum-Si and Planet Innovation to Partner on Proteus™

Document Date: Nov. 20, 2024, 11 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership: Document Extract: Quantum-Si and Planet Innovation to Partner on Proteus™. Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si ," "QSI" or the "Company") , The Protein Sequencing Company™, and Planet Innovation today announced that they will partner on the development and manufacturing of Quantum-Si's novel proteomics platform, Proteus™. Planet Innovation has a team of over four hundred people with expertise across design, development and manufacturing of scientific instrumentation and medical devices. Currently, Planet Innovation serves as the contract manufacturer for Quantum-Si's Platinum® Pro instrument, set to debut in the first half of 2025. Through this expanded partnership, Planet Innovation will support the development of Quantum-Si's Proteus instrument and serve as the contract manufacturing partner to ensure a seamless transition from development into commercialization.
Document Source: https://www.businesswire.com/news/home/20241120378566/en/Quantum-Si-and-Planet-Innovation-to-Partner-on-Proteus%25E2%2584%25A2 (archive.org page / archive.org listing)


Quantum-Si and Planet Innovation to Partner on Proteus™

Document Date: Nov. 20, 2024, 11 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership: Document Extract: Planet Innovation has a team of over four hundred people with expertise across design, development and manufacturing of scientific instrumentation and medical devices. Currently, Planet Innovation serves as the contract manufacturer for Quantum-Si's Platinum® Pro instrument, set to debut in the first half of 2025. Through this expanded partnership, Planet Innovation will support the development of Quantum-Si's Proteus instrument and serve as the contract manufacturing partner to ensure a seamless transition from development into commercialization. " We are thrilled to expand our partnership with Planet Innovation and leverage their global scale and expertise to accelerate the development and commercialization of Proteus ," said Jeff Hawkins, President and CEO of Quantum-Si. " We believe that partnering with Planet Innovation will allow us to deliver this novel instrument to the market on a timeline of under two years ."
Document Source: https://www.businesswire.com/news/home/20241120378566/en/Quantum-Si-and-Planet-Innovation-to-Partner-on-Proteus%25E2%2584%25A2 (archive.org page / archive.org listing)


Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering

Document Date: Nov. 22, 2024, 2:15 p.m. / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity / Type: Ipo / Region: United States
Vendor: Document Extract: THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) - Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company") , a medical device company focused on advancing precision nerve-targeted treatments, today announced the pricing of an underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $ 9.0 million prior to deducting underwriting discounts and commissions and offering expenses.
Document Source: https://www.globenewswire.com/news-release/2024/11/22/2986021/0/en/Autonomix-Medical-Inc-Announces-Pricing-of-9-0-Million-Underwritten-Public-Offering.html (archive.org page / archive.org listing)


Positron Corporation Partners With Upbeat Cardiology Solutions to Expand Cardiac PET-CT Offerings

Document Date: Nov. 21, 2024, 2:30 p.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity / Region: Niagara Falls
Partnership: Document Extract: With Positron's cutting-edge NeuSight PET-CT 64 Slice scanner at the core of these solutions, practices can offer the highest level of care, backed by a platform that combines clinical excellence with economic efficiency. Patrick O'Keefe, President of Upbeat Cardiology Solutions stated, "As a leader in innovation and turnkey solutions in the nuclear cardiology space we see our partnership with Positron as a step closer to our goal of bringing access of care to cardiology practices nationwide. Through this partnership we have another avenue to bring high end technologies into affordable camera lease and purchase options, overcoming a major cost obstacle and opening the door to cardiac practices of all sizes ." " Upbeat Cardiology Solutions excels in integrating advanced nuclear cardiology technology into practices and this collaboration is a strategic step forward in broadening access to our PET-CT technology and clinical services for all cardiology practices ," said Adel Abdullah, President of Positron Corporation. " Our NeuSight PET-CT 64 slice is an ideal solution to meet the rising demand for superior diagnostic tools in cardiac imaging.
Document Source: https://www.globenewswire.com/news-release/2024/11/21/2985327/0/en/Positron-Corporation-Partners-With-Upbeat-Cardiology-Solutions-to-Expand-Cardiac-PET-CT-Offerings.html (archive.org page / archive.org listing)


Smart ring maker Oura picks up $75M series D, inks strategic partnership with Dexcom

Document Date: Nov. 19, 2024, 11 a.m. / Source: Fierce Healthcare
Activity Class: PartnershipActivity
Partnership: Document Extract: Smart ring maker Oura picks up $ 75M series D, inks strategic partnership with Dexcom. Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring, which tracks sleep, heart rate and activity. Oura also picked up $ 75 million from Dexcom in a series D funding round, valuing the company at more than $ 5 billion, the company announced Tuesday. The company, which launched out of Finland as a sleep tracking smart ring in 2015, has now sold 2.5 million rings. It expects to see annual sales double in 2024 to roughly $ 500 million, and the company is profitable, according to Oura CEO Tom Hale.
Document Source: https://www.fiercehealthcare.com/digital-health/smart-ring-maker-oura-picks-75m-series-d-inks-strategic-partnership-dexcom (archive.org page / archive.org listing)


BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

Document Date: Nov. 20, 2024, noon / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity / Type: Acquisition
Vendor: Buyer: Document Extract: POMPANO BEACH, Fla., Nov. 20, 2024 (GLOBE NEWSWIRE) - BioStem Technologies Inc. (OTC: BSEM) , a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today announced the signing of a Letter of Intent (LOI) to acquire commercial-stage products and development technologies from ProgenaCare Global LLC ("ProgenaCare") , a pioneering medical device company leveraging cutting-edge advances in biomaterials to provide effective, affordable advanced wound care solutions.
Document Source: https://www.globenewswire.com/news-release/2024/11/20/2984274/0/en/BioStem-Technologies-Signs-Letter-of-Intent-to-Acquire-Wound-Care-Products-and-Technologies-from-ProgenaCare-Global.html (archive.org page / archive.org listing)


Zenflow Announces $24 Million Financing Round to Fund FDA Filing & Commercial Preparation

Document Date: Nov. 19, 2024, 12:34 a.m. / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity / Type: Investment / Region: United States
Investor: Target: Document Extract: Zenflow Announces $ 24 Million Financing Round to Fund FDA Filing & Commercial Preparation.
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983218/0/en/Zenflow-Announces-24-Million-Financing-Round-to-Fund-FDA-Filing-Commercial-Preparation.html (archive.org page / archive.org listing)


Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Document Date: Nov. 22, 2024, 8:09 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity
Partnership: Document Extract: As part of the next phase of the RemeOs™ Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals. " We are happy to announce this sales and distribution agreement with a partner who is innovative in forming medical product distribution streams in the U.S. The initial controlled launch of RemeOs™ Trauma Screws in the U.S. yielded excellent patient results, with a notable number of surgeries and successful post-healing follow-ups. This success lays the groundwork for entering the second phase of commercialization for RemeOs™ products in the U.S. and driving demand within the surgeon community", says Alan Donze, CEO of Bioretec Ltd. Further enquiries.
Document Source: https://www.prnewswire.com/news-releases/bioretec-signed-a-new-sales-and-distribution-agreement-to-accelerate-the-commercialization-of-remeos-trauma-screw-in-the-us-civilian-hospital-market-302314033.html (archive.org page / archive.org listing)


Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Document Date: Nov. 22, 2024, 8:09 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: Bailiwick of Jersey
Partnership: Document Extract: TAMPERE, Finland, Nov. 22, 2024 /PRNewswire/ - Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs™ Trauma Products in the U.S. market. As a continuation to the previously signed logistics agreement with GlobalMed Logistix, Bioretec strengthens now its commercialization efforts by signing a new sales and distribution agreement with Tri-State Biologics (TSB) , which is a distributor of medical and surgical products based in New Jersey. TSB is a leading medical solutions provider with 18 sales representatives dedicated to breaking the mold of traditional medical device distribution. Signing of the agreement will enable the smooth sales and distribution of implants and instrument sets to hospitals within Greater New York City, Philadelphia, New Jersey, Connecticut, and Massachusetts area covering one of the most populated areas of the United States. As part of the next phase of the RemeOs™ Trauma Screw commercialization, Bioretec aims to sign more new local sales and distribution agreements to serve civilian hospitals in the U.S. while Spartan Medical continues to serve the military and veteran hospitals.
Document Source: https://www.prnewswire.com/news-releases/bioretec-signed-a-new-sales-and-distribution-agreement-to-accelerate-the-commercialization-of-remeos-trauma-screw-in-the-us-civilian-hospital-market-302314033.html (archive.org page / archive.org listing)


MIT Sloan Professor Steven Eppinger Joins SurgiBox's Board of Directors

Document Date: Nov. 22, 2024, 1:17 p.m. / Source: PR Newswire
Activity Class: RoleActivity / Type: Starting / Region: Cambridge, United States
Role: Person: Organization: Document Extract: MIT Sloan Professor Steven Eppinger Joins SurgiBox's Board of Directors.
Document Source: https://www.prnewswire.com/news-releases/mit-sloan-professor-steven-eppinger-joins-surgiboxs-board-of-directors-302313037.html (archive.org page / archive.org listing)


Erica Rogers Joins the Board of Directors at Axena Health, Bringing Proven Commercial Leadership and Expertise in Groundbreaking Healthcare Solutions

Document Date: Nov. 19, 2024, 1:30 p.m. / Source: Business Wire
Activity Class: RoleActivity / Type: Starting / Region: United States
Role: Person: Organization: Document Extract: Axena Health, Inc. (Axena Health) , a medical device company focused on female pelvic health, today announced the appointment of Erica Rogers to its Board of Directors.
Document Source: https://www.businesswire.com/news/home/20241119812886/en/Erica-Rogers-Joins-the-Board-of-Directors-at-Axena-Health-Bringing-Proven-Commercial-Leadership-and-Expertise-in-Groundbreaking-Healthcare-Solutions (archive.org page / archive.org listing)


AdvaMed Statement on President-elect Trump's Intent to Nominate Dr. Oz to Lead CMS

Document Date: Nov. 19, 2024, 11:25 p.m. / Source: PR Newswire
Activity Class: RoleActivity / Type: Starting / Region: Washington
Role: Person: Organization: Document Extract: WASHINGTON, Nov. 19, 2024 /PRNewswire/ - AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker on President-elect Trump's announcement that he intends to nominate Dr. Mehmet Oz to serve as Administrator of the Centers for Medicare & Medicaid Services:
Document Source: https://www.prnewswire.com/news-releases/advamed-statement-on-president-elect-trumps-intent-to-nominate-dr-oz-to-lead-cms-302310683.html (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? No (Turn On)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.